Hyperimmune globulin and monoclonal antibody for the treatment of SARS CoV-2 infection

Autores

  • Oswaldo Jesus Rodrigues da Motta Universidade Federal de Viçosa - UFV, Viçosa, Minas Gerais, Brazil, oswaldojrm@hotmail.com
  • Andreia Patricia Gomes Universidade Federal de Viçosa - UFV, Viçosa, Minas Gerais, Brazil, andreia.gomes@ufv.br
  • Leandro Almeida de Oliveira Faculdade Dinâmica do Vale do Piranga - FADIP, Ponte Nova, Minas Gerais, Brazil, steamleandro@hotmail.com
  • Leonardo de Almeida Oliveira Faculdade Dinâmica do Vale do Piranga - FADIP, Ponte Nova, Minas Gerais, Brazil, leo-almeida-@hotmail.com
  • Caio Henrique Santos Almeida Universidade Federal de São João del-Rei - UFSJ, São João del-Rei, Minas Gerais, Brazil, caiohenriquesantosalmeida@gmail.com
  • Luciene Muniz Braga Universidade Federal de Viçosa - UFV, Viçosa, Minas Gerais, Brazil, luciene.muniz@ufv.br

DOI:

https://doi.org/10.5216/rpt.v49i4.65396

Resumo

The current pandemic of COVID-19 (Coronavirus Disease-19), caused by the pathogen SARSCoV-2, leading to thousands of deaths in 2020, has mobilized the scientific community, with the purpose of understanding the different aspects of the disease and proposing new treatment and prevention measures. Research carried out in several areas includes evaluating the possibility of using hyperimmune globulin and monoclonal antibodies against SARS CoV-2 as well as analyzing the viability and efficacy of monoclonal antibodies and hyperimmune globulin in combating Sars-CoV-2. A literature review was carried out with a defined search strategy using the keywords (i) “hyperimmune globulin”, (ii) “monoclonal antibody”, (iii)“ covid-19” and (iv)“ sars-cov-2”, in the PubMed and ResearchGate databases, using the bibliographic references of the articles selected in these databases. Of the 187 citations obtained, 10 articles published between 2019 and 2020 were selected after reading the summary of each one and determining its compatibility with the objective of this study. Final considerations highlight the main challenges and the feasibility of using hyperimmune globulin and monoclonal antibodies for the treatment/prevention of SARS CoV-2 infection.
KEY WORDS: Hyperimmune globulin; monoclonal antibody; COVID-19; SARS-CoV-2.

Downloads

Não há dados estatísticos.

Biografia do Autor

Oswaldo Jesus Rodrigues da Motta, Universidade Federal de Viçosa - UFV, Viçosa, Minas Gerais, Brazil, oswaldojrm@hotmail.com

1. Universidade Federal de Viçosa (UFV). Department of Medicine and Nursing. Viçosa, Minas Gerais, Brazil.
2. Università degli Studi di Torino. Department of Public Health Sciences and Pediatrics. Turin, Italy.

Andreia Patricia Gomes, Universidade Federal de Viçosa - UFV, Viçosa, Minas Gerais, Brazil, andreia.gomes@ufv.br

Universidade Federal de Viçosa (UFV). Department of Medicine and Nursing. Viçosa, Minas Gerais, Brazil.

Leandro Almeida de Oliveira, Faculdade Dinâmica do Vale do Piranga - FADIP, Ponte Nova, Minas Gerais, Brazil, steamleandro@hotmail.com

Faculdade Dinâmica (FADIP). Graduating in Medicine. Ponte Nova, Minas Gerais, Brazil.

Leonardo de Almeida Oliveira, Faculdade Dinâmica do Vale do Piranga - FADIP, Ponte Nova, Minas Gerais, Brazil, leo-almeida-@hotmail.com

Faculdade Dinâmica (FADIP). Graduating in Medicine. Ponte Nova, Minas Gerais, Brazil.

Caio Henrique Santos Almeida, Universidade Federal de São João del-Rei - UFSJ, São João del-Rei, Minas Gerais, Brazil, caiohenriquesantosalmeida@gmail.com

Universidade Federal de São João del-Rei (UFSJ). Graduating in Medicine. São João del-Rei, Minas Gerais, Brazil.

Luciene Muniz Braga, Universidade Federal de Viçosa - UFV, Viçosa, Minas Gerais, Brazil, luciene.muniz@ufv.br

Universidade Federal de Viçosa (UFV). Department of Medicine and Nursing. Viçosa, Minas Gerais, Brazil.

Downloads

Publicado

2021-01-11

Como Citar

JESUS RODRIGUES DA MOTTA, O.; PATRICIA GOMES, A.; ALMEIDA DE OLIVEIRA, L.; DE ALMEIDA OLIVEIRA, L.; HENRIQUE SANTOS ALMEIDA, C.; MUNIZ BRAGA, L. . Hyperimmune globulin and monoclonal antibody for the treatment of SARS CoV-2 infection. Revista de Patologia Tropical / Journal of Tropical Pathology, Goiânia, v. 49, n. 4, p. 215–227, 2021. DOI: 10.5216/rpt.v49i4.65396. Disponível em: https://revistas.ufg.br/iptsp/article/view/65396. Acesso em: 26 dez. 2024.

Edição

v. 49 n. 4 (2020)

Seção

REVISÃO / REVIEW

Licença

The manuscript submission must be accompanied by a letter signed by all authors stating their full name and email address, confirming that the manuscript or part of it has not been published or is under consideration for publication elsewhere, and agreeing to transfer copyright in all media and formats for Journal of Tropical Pathology.